Purine analog toxicity in patients with hairy cell leukemia

Leukemia and Lymphoma

Volumn 52, Issue SUPPL. 2, 2011, Pages 38-42

  Tadmor, Tamar ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Hairy cell leukemia; purine analogs; second malignancy; stem cell toxity

Indexed keywords

CLADRIBINE; PENTOSTATIN;

ARTICLE; CYTOTOXICITY; GERIATRIC PATIENT; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEUROTOXICITY; PREGNANCY; PRIORITY JOURNAL; STEM CELL;

ANTINEOPLASTIC AGENTS; CLADRIBINE; HUMANS; LEUKEMIA, HAIRY CELL; PURINES; VIDARABINE;

EID: 79957438295     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.565097     Document Type: Article

References (25)

1. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918-1926. (Pubitemid 28446680)
2. Bourguin-Plonquet A, Rouard H, Roudot-Thoraval F, et al. Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia. Br J Haematol 2002;116: 595-597. (Pubitemid 34178658)
3. Dasanu CA, Ichim T, Alexandrescu DT. Inherent and iatrogenic immune defects in hairy cell leukemia: revisited. Expert Opin Drug Saf 2010;9:55-64.
4. Arons E, Sorbara L, Raffeld M, et al. Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy. Cancer Immunol Immunother 2006;55:1100-1110. (Pubitemid 43800725)
5. Brunetti L, Di Noto R, Abate G, et al. CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. Br J Haematol 2009;145:665-667.
6. Ruco L, Procopio A, Maccallini V, et al. Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. Blood 1983;61:1132-1137. (Pubitemid 13099901)
7. Urba W, Baseler M, Kopp W, et al. Deoxycoformycininduced immunosuppression in patients with hairy cell leukemia. Blood 1989;73:38-46. (Pubitemid 19040951)
8. Kraut EH, Neff JC, Bouroncle BA, Gochnour D, Grever MR. Immunosuppressive effects of pentostatin. J Clin Oncol 1990;8:848-855. (Pubitemid 20148277)
9. Seymour JF, Talpaz M, Kurzrock R. Response duration and recovery of CD4\+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year followup. Leukemia 1997;11:42-47. (Pubitemid 27065048)
10. Seymour JF, Kurzrock R, Freireich E, Estey E. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4\+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994;83:2906-2911. (Pubitemid 24142723)
11. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994;83: 3672-3681. (Pubitemid 24175558)
12. Schirmer M, Hilbe W, Geisen F, Thaler J, Konwalinka G. T cells and natural killer cells after treatment of hairy cell leukaemia with 2-chlorodeoxyadenosine. Acta Haematol 1997;97:180-183. (Pubitemid 27067416)
13. Federico M, Zinzano PL, Frassoldati A, et al. Risk of second cancer in patients with hairy cell leukemia: long-term followup. J Clin Oncol 2002;20:638-646. (Pubitemid 34111369)
14. Hisada M, Chen B, Jaffe E, Travis LB. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 2007;99:215-222.
15. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term followup of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000;96:2981-2986.
16. Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM. Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood 1998;92: 1160-1164. (Pubitemid 28369028)
17. Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007-3015. (Pubitemid 28417420)
18. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733-740.
19. Leupin N, Schuller JC, Solenthaler M, et al. Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). Leuk Lymphoma 2010;51:613-619.
20. Todd SA, Morris TC, Alexander HD. Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin. Leuk Lymphoma 2002;43:1343-1344. (Pubitemid 34537984)
21. Hassan R, Gupta M, Kern W, Ozer H. Acute myeloid leukemia following treatment with cladribine for hairy cell leukemia: a case report and review of the literature. Leuk Lymphoma 2004;45:2149-2152. (Pubitemid 39232867)
22. Carney DA, Westerman DA, Tam CS, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010;24:2056-2062.
23. Gillis S, Amir G, Bennett M, Polliack A. Unexpectedly high incidence of hypoplastic/aplastic foci in bone marrow biopsies of hairy cell leukemia patients in remission following 2- chlorodeoxyadenosine therapy. Eur J Haematol 2001;66:7-10. (Pubitemid 32099403)
24. Siegel RS, Hakimian D, Spies W, et al. Technetium-99M sulfur colloid scanning and correlative magnetic resonance imaging in patients with hairy cell leukemia and hypocellular bone marrow biopsies after 2-chlorodeoxyadenosine. Leuk- Lymphoma 1999;35:171-177. (Pubitemid 29454414)
25. Orlowsky RZ. Successful pregnancy after cladribine therapy for hairy cell leukemia. Leuk Lymphoma 2004;45:187-188.